Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.
Paolo Antonio AsciertoMichele Del VecchioAndrzej MackiewiczCaroline RobertVanna Chiarion-SileniAna AranceCéleste LebbéInge Marie SvaneCatriona McNeilPiotr Lukasz RutkowskiCarmen LoquaiLaurent MortierOmid HamidLars BastholtBrigitte DrenoDirk SchadendorfClaus GarbeMarta NyakasJean-Jacques GrobLuc ThomasGabriella LiszkayMichael SmylieChristoph HoellerVirginia FerraresiFlorent GrangeRalf GutzmerJoanna PikielFareeda HoseinBurcin SimsekMichele MaioPublished in: Journal for immunotherapy of cancer (2021)
NCT01515189.